Tonsil enlargement after liver transplantation in adults - Reason enough for tonsillectomy? Two cases of tonsillar posttransplantation lymphoproliferative disease

Liver Transplantation

Volumn 13, Issue 6, 2007, Pages 918-923

  Mucha, Krzysztof ^a   Foroncewicz, Bartosz ^a   Niemczyk, Kazimierz ^a   Ziarkiewicz Wróblewska, Bogna ^a   Stanisławek Sut, Olimpia ^a   Zieniewicz, Krzysztof ^a   Krawczyk, Marek ^a   Paczek, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CYCLOSPORIN; GANCICLOVIR; GLUCOCORTICOID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REMISSION; SURGICAL RISK; TONSIL DISEASE; TONSILLECTOMY;

ADULT; FEMALE; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; TONSIL; TONSILLECTOMY;

EID: 34250654523     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21177     Document Type: Article

References (30)

1. Mamzer-Bruneel MF, Bourquelot P, Hermine O, Legendre C, Kreis H. Treatment and prognosis of post-transplant lymphoproliferative disease. Ann Transplant 1997;2:42-48.
2. Boubenider S, Hiesse C, Goupy C, Kriaa F, Marchand S, Charpentier B. Incidence and consequences of posttransplantation lymphoproliferative disorders. J Nephrol 1997; 10:136-145.
3. Swinnen LJ. Diagnosis and treatment of transplant-related lymphoma. Ann Oncol 2000; 11:45-48.
4. Young L, Alfieri C, Hennessy K, Evans H, O'Hara C, Anderson KC, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321: 1080-1085.
5. Yang J, Tao Q, Flinn IW, Murray PG, Post LE, Ma H, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-4063.
6. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-230.
7. Aucejo F, Rofaiel G, Miller C. Who is at risk for post-transplant lymphoproliferative disorders (PTLD) after liver transplantation? J Hepatol 2006;44:19-23.
8. Langrehr JM, Glanemann M, Guckelberger O, Klupp J, Neumann U, Machens C, et al. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppression induction therapy after liver transplantation. Clin Transpl 1998; 12:303-312.
9. Dufour JF, Fey MF. What is the current treatment of PTLD after liver transplantation? J Hepatol 2006;44:23-26.
10. Kremers WK, Devarbhavi HC, Wiesner RH, Kroma RAF, Macona WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transpl 2006;6: 1017-1024.
11. Leblond V, Davi F, Charlotte F, Dorent R, Bitker MO, Sutton L, et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998; 16:2052-2059.
12. Leblond V, Choquet S. Lymphoproliferative disorders after liver transplantation. J Hepatol 2004;40:728-735.
13. Loevner LA, Karpati RL, Kumar P, Yousem DM, Hsu W, Montone KT. Posttransplantation lymphoproliferative disorder of the head and neck: imaging features in seven adults. Radiology 2000;216:363-269.
14. Wu L, Rappaport DC, Hanbidge A, Merchant N, Shepherd FA, Greig PG. Lymphoproliferative disorders after liver transplantation: imaging features. Abdom Imaging 2001; 26:200-206.
15. Shapiro NL, Strocker AM, Bhattacharyya N. Risk factors for adenotonsillar hypertrophy in children following solid organ transplantation. Int J Pediatr Otorhinolaryngol. 2003;67:151-155.
16. De Diego JI, Prim MP, Hardisson D, Verdaguer JM, Jara P. Post-transplant lymphoproliferative disease in tonsils of children with liver transplantation. Int J Pediatr Otorhinolaryngol 2001;27;58:113-118.
17. Koh BY, Rosenthal P, Medeiros LJ, Osorio RW, Roberts JP, Ascher NL, et al. Posttransplantation lymphoproliferative disorders in pediatric patients undergoing liver transplantation. Arch Pathol Lab Med 2001; 125:337-343.
18. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001;71: 1076-1088.
19. Rowe DT, Webber S, Schauer EM, Reyes J, Green M. Epstein-Barr virus load monitoring: its role in the prevention and management of post-transplant lymphoproliferative disease. Transpl Infect Dis 2001;3:79-87.
20. Foroncewicz B, Mucha K, Usiekniewicz J, Chmura A, Kryst P, Soldacki D, Paczek L. Posttransplant lymphoproliferative disorder of the lung in a renal transplant recipient treated successfully with surgery. Transplant Proc 2006;38:173-176.
21. Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107:3053-3057.
22. Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005;5:2901-2906.
23. Nouwen J, Smets F, Rombaux P, Hamoir M, Sokal EM. Acute tonsillitis as the first manifestation of post-transplant lymphoproliferative disorder. Ann Otol Rhinol Laryngol 2002;111:165-168.
24. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003;3:801-812.
25. Lazda VA. Evaluation of Epstein-Barr virus (EBV) antibody screening of organ donors for allocation of organs to EBV serostatus matched recipients. Transplant Proc 2006;38:3404-3405.
26. Shaknovich R, Basso K, Bhagat G, Mansukhani M, Hatzivassiliou G, Murty VV, et al. Identification of rare Epstein-Barr virus infected memory B cells and plasma cells in non-monomorphic post-transplant lymphoproliferative disorders and the signature of viral signaling. Haematologica 2006;91:1313-1320.
27. Scheenstra R, Verschuuren EA, de Haan A, Slooff MJ, The TH, Bijleveld CM, et al. The value of prospective monitoring of Epstein-Barr virus DNA in blood samples of pediatric liver transplant recipients. Transpl Infect Dis 2004;6: 15-22.
28. Wagner HJ, Wessel M, Jabs W, Smets F, Fischer L, Offner G, et al. Patients at risk for development of posttransplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001;72: 1012-1019.
29. Tursi A, Brandimarte G, Torello M. Disappearance of gastric mucosa-associated lymphoid tissue in hepatitis C virus-positive patients after anti-hepatitis C virus therapy. J Clin Gastroenterol 2004;38:360-363.
30. Shpilberg O, Wilson J, Whiteside TL, Herberman RB. Pretransplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma 1999;36:109.